期刊文献+

大剂量阿托伐他汀治疗不稳定性心绞痛的临床观察 被引量:2

下载PDF
导出
摘要 目的探讨大剂量阿托伐他汀治疗不稳定性心绞痛(UA)的临床疗效和安全性。方法将118例UA患者随机分成两组,治疗组(阿托伐他汀40mg/日)和对照组(阿托伐他汀10mg/日),观察两组患者用药后3个月的临床效果、血脂水平及不良反应。结果①两组患者服用阿托伐他汀4周、12周时的脂质水平变化比较,用药12周治疗组的TC、LDL下降明显,与对照组相比差异有统计学意义(P<0.05);②两组治疗后心绞痛发作次数和平均发作持续时间较治疗前均有好转;治疗组与对照组相比,心绞痛发作次数和平均发作持续时间治疗前无差异,治疗后差异明显,有统计学意义(P<0.05);③治疗组83.1%(49/59)的患者心电图有改善,对照组66.1%(39/59)的患者心电图有改善,④服药一周后两组(治疗组23例/对照组12例)均有谷丙转氨酶轻度升高(<3倍),两组差异有统计学意义(P<0.005),但均无明显升高>3倍),两组肾功能、肌酸激酶无明显变化。结论使用大剂量阿托伐他汀(40mg/日)治疗UA,临床疗效显著,无严重不良反应。
出处 《中国现代药物应用》 2008年第21期31-32,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献5

二级参考文献24

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2208

同被引文献21

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部